IGM Biosciences, Inc. (IGMS)
- Previous Close
1.1900 - Open
1.2100 - Bid 0.8496 x 200
- Ask 1.4800 x 200
- Day's Range
1.1400 - 1.2100 - 52 Week Range
0.9200 - 22.5000 - Volume
70,062 - Avg. Volume
181,431 - Market Cap (intraday)
69.062M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-3.2400 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.88
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
igmbio.comRecent News: IGMS
View More
Performance Overview: IGMS
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IGMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IGMS
View MoreValuation Measures
Market Cap
69.06M
Enterprise Value
-69.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
25.98
Price/Book (mrq)
1.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.23%
Return on Equity (ttm)
-155.76%
Revenue (ttm)
2.68M
Net Income Avi to Common (ttm)
-195.8M
Diluted EPS (ttm)
-3.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
183.79M
Total Debt/Equity (mrq)
93.80%
Levered Free Cash Flow (ttm)
-85.9M